BHC · Bausch Health Companies Inc

The thesis

Bausch Health's operating recovery now has a company-confirmed next step: on 12 October 2026 it said it expects to raise 2026 adjusted EBITDA guidance, but $20.2 billion of debt principal keeps the equity fragile. The third-quarter report on 28 October 2026 settles how large the raise is and whether debt has fallen.

The narrative is maturing: the guidance raise was pre-announced on 12 October 2026, so the report confirms a known direction and the open question is the size. The shares closed at $6.45 on 21 October 2026, 18.4% below the 52-week high of $7.90 and up 45.6% over three months (adjusted daily closes). The 14-day Relative Strength Index (RSI), a momentum gauge on a 0–100 scale, reads 78.6, above the 70 mark often read as overbought.

Bausch Health will report after the market close on 28 October 2026, with a call at 5:00 p.m. U.S. Eastern time. Bausch + Lomb reports the same day.

Bullish and bearish views on Bausch Health Companies Inc

The bull case on Bausch Health Companies Inc (BHC), in brief: Raise already signalled by the company. The bear case: Debt absorbs operating gains.

Bull case

• Raise already signalled by the company. On 12 October 2026 Bausch Health and Bausch + Lomb said, based on preliminary third-quarter results, they expect to raise full-year 2026 adjusted EBITDA guidance excluding acquired in-process research and development (8-K exhibit). The release gives no dollar figure; the current Bausch Health range excluding Bausch + Lomb is $3.025–3.100 billion.
• Growth streak. The 12 October 2026 release states that Bausch Health excluding Bausch + Lomb has posted 13 consecutive quarters of year-over-year growth in revenue and adjusted EBITDA.
• Adjusted EBITDA rose 28% to $1,075 million.
• Salix pilot data. On 12 October 2026 Salix said a cirrhosis care pathway pilot raised hepatic encephalopathy treatment rates from 60.2% to 64.9%, which supports demand for Xifaxan.
• Eye-health stake. The Form 10-Q for the period ended 30 June 2026 showed about 87% ownership of Bausch + Lomb; full separation depends on leverage targets and approvals.

Bear case

• Debt absorbs operating gains. The Form 10-Q reported $20,239 million of contractual debt principal at 30 June 2026 and $798 million of first-half interest expense. No later debt figure has been published.
• Bausch + Lomb leadership change. On 12 October 2026 Bausch + Lomb CEO Brent Saunders left by mutual agreement with the board. Thomas Appio, who is also Bausch Health's CEO, became interim CEO with no timeline for a permanent hire (8-K exhibit). Bausch + Lomb shares fell that day, per a Benzinga headline.
• Salix is impaired. The 10-Q recorded a $1,426 million goodwill impairment for Salix after failed Phase 3 trials. The Xifaxan intangible carried $808 million with about 18 months of estimated remaining life.
• The good news is partly in the price. The shares closed at $6.04 on 8 October 2026, before the 12 October 2026 announcement, and at $6.45 on 21 October 2026. The report must beat an expected raise, not merely deliver one.
• Analyst targets sit near the price. Investing.com pages list an average 12-month target of about $7.30 to $7.50 across five analysts, with a low of $6.50. RBC Capital cut its target to $9 from $10 on 27 April 2026, and Barclays cut to $7 from $8 on 25 February 2026. No target changes after the October announcement were found.

Price setup

The last adjusted close was $6.45 on 21 October 2026. The 52-week high is $7.90, reached after the 29 July 2026 report. The post-earnings low was the $5.69 close on 25 September 2026.

The shares have risen 13.5% from the $5.69 low to the 21 October 2026 close with an RSI of 78.6, so the move into the report is stretched. The report lands six days after the latest close, and a levered equity can move sharply on a small change in guidance or debt.

Catalysts, next 30 days

No upcoming dated catalysts on file — the dated entries below have passed.

Elapsed catalysts

• 28 October 2026 (after market close): Bausch Health third-quarter 2026 results and call at 5:00 p.m. U.S. Eastern time. This shows the new adjusted EBITDA range excluding Bausch + Lomb and any change in debt principal from $20,239 million. (passed 9d ago)
• 28 October 2026: Bausch + Lomb third-quarter results, with its own raised guidance expected. The current range is $1.025–1.075 billion, and the report may add detail on the CEO search. (passed 9d ago)

What would change the view

The case breaks if the 28 October 2026 report delivers a smaller raise than the 12 October 2026 release implied, shows no reduction in debt principal, or states that leverage targets for the Bausch + Lomb separation remain unmet. A new impairment beyond the $1,426 million Salix charge would also weaken it. On price, a daily close below $5.60, under the 25 September 2026 close of $5.69, would erase the September rebound and end the case.

A raise well above the $3.025–3.100 billion range, together with a lower debt figure, would strengthen it.

What it trades with

Bausch Health consolidates Bausch + Lomb (ticker BLCO), so the two stocks react to the same eye-health results and to the 12 October 2026 leadership change. The shares trade as a leveraged equity: the change in debt matters as much as the earnings figure. Salix and Xifaxan results drive the pharmaceutical side independently of eye care.